Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
Posted: November 20, 2024 at 2:48 am
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from one late-breaker oral and three poster presentations at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting (TLM) 2024, being held November 15 – 19, 2024 in San Diego, CA.
Link:
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
Posted in Global News Feed
Comments Off on Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference
Posted: November 20, 2024 at 2:48 am
MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 36th Annual Healthcare Conference.
Go here to read the rest:
TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference
Posted in Global News Feed
Comments Off on TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
Posted: November 20, 2024 at 2:48 am
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date for its previously-announced share consolidation. At its Annual General and Special Meeting of Shareholders, which was held on November 12, 2024, Psyence Biomed’s shareholders approved a consolidation of the Company’s common shares at a ratio of up to 1 common share for every 75 common shares held, with the final ratio to be determined by the Company’s board of directors (the “Board”). Also, as previously announced, the Board approved a 1-for-75 consolidation of its outstanding common shares.
Go here to see the original:
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
Posted in Global News Feed
Comments Off on Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
Posted: November 20, 2024 at 2:48 am
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
More:
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
Posted in Global News Feed
Comments Off on Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
Posted: November 20, 2024 at 2:48 am
REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024, in New York, New York.
Excerpt from:
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
Posted in Global News Feed
Comments Off on Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™
Posted: November 20, 2024 at 2:48 am
Targeting Transformative Solutions for Aplastic Anemia and Beyond
Read more:
Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™
Posted in Global News Feed
Comments Off on Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance…
Posted: November 20, 2024 at 2:48 am
WARREN, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, has announced financial results for the fiscal quarter ending September 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission.
Posted in Global News Feed
Comments Off on Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance…
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
Posted: November 20, 2024 at 2:48 am
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today announces the appointment of Simon Fry to its Board of Directors.
More:
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
Posted in Global News Feed
Comments Off on Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
Posted: November 20, 2024 at 2:48 am
FREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that it has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Breakthrough Awards program. This program is conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe. This year’s program attracted thousands of nominations from 14 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.
Go here to see the original:
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
Posted in Global News Feed
Comments Off on Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Posted: November 20, 2024 at 2:48 am
November 20, 2024, 7:00 AM CET
See original here:
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Posted in Global News Feed
Comments Off on argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
